Vivek Arora

About Vivek Arora

• Preclinical assessment of mechanisms of resistance to hormone therapy in prostate cancer has led to the discovery and development of a new medicine, named ARN-509.
• Dr. Arora has shown that one mechanism of resistance to ARN-509 is the induction of a new hormone receptor, designated Glucocorticoid Receptor (GR).
• It is believed that GR can, in part, replace the androgen receptor, the engine of prostate cancer progression, causing the patient to become drug resistant.
• Dr. Arora will test this idea in models of progressive disease and prostate cancer patients, with inhibitors of GR.

What this means to patients: A qualified inhibitor to the glucocorticoid receptor (GR) could be a new treatment for drug-resistant patients with advanced, metastatic prostate cancer.